Trial Profile
A One-year Open-label Extension to a Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate Efficacy and Safety of Deferasirox in Non-transfusion-dependent Thalassemia Patients With Iron Overload (THALASSA)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Deferasirox (Primary)
- Indications Thalassaemia
- Focus Therapeutic Use
- Acronyms THALASSA
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Sep 2014 New trial record
- 10 Sep 2014 New trial record